Just days after we covered the story on Quantum Leap Energy’s non-binding MOU with a major U.S. nuclear utility, Canaccord Genuity analyst George Gianarikas reiterated his buy rating on the beaten down ASP Isotopes, with an $11 price target citing “material progress” toward commercial uranium enrichment on two continents. On February 23, QLE inked a Pre-Implementation Services Contract with South Africa’s Necsa to site, design, build, and operate an enrichment facility at the Pelindaba complex. The deal gives QLE access to existing nuclear infrastructure, utilities, and a joint oversight committee. Gianarikas says it’s the clearest signal yet that licensed HALEU production in South Africa is moving from lab to market readiness. The March 6 MOU we highlighted last week adds the U.S. piece: the unnamed utility will potentially help stand up domestic HALEU and LEU+ enrichment, conversion, and deconversion capacity while discussing offtake and financing. That’s critical ahead of the 2028 Russian uranium import ban we’ve repeatedly flagged as the biggest catalyst for non-adversarial supply chains. The report also spotlights accelerating LEU+ adoption by conventional …